The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Useful - thanks Sanjijuelas1
And as milestone payments total $347m for each vaccine taken to market, part of milestone might be triggered on delivery of candidates for further research by MSD
Funds until Q2 next year although an additional fund raise later in the year wouldn't be that surprising or maybe a shelf registration on Nasdaq.
Another possibility is out licensing the development of Blautix and maybe Thetanix, which could bring in £25-50m upfront payment.
If they deliver candidates to MSD for the vaccine collaboration that would represent a serious validation of the Micro RX platform and would likely mean other partners paying upfront to use the platform for candidate discovery.
@Rocket79
I'm totally expecting those to be hyped to the moon only to disappoint when the traders sell on the news. But if we can maintain a higher bottom price after them all will be good. I'm kinda expecting this share to go back and forth between 105p and 125p until we get close to the June news and then you'll see a lot of new faces on this board.
When do people anticipate the next fund raise? By my poor assessment of their latest financial report they have cash for about a year. Is that a fair assumption?
Maybe converted to ADS as these shown as a separate holding of 16% on 4D Shareholder info page
It relates back to the merger, how strange.
I expect a holding rns at 2.26 pm
Yeah I think we're years off... years off becoming a multibillion pound company. In the meantime there should be many key milestones that will take us to £300m, £400m, £600m etc
Oncology readouts June, September this year. With Asthma in Q3.
Cure cancer this year cure ibs next year and Parkinson cure 2023
That’s some ninja-style subtle de-ramping there, Splodge.
I've held this share since October. I'm wondering if we're years off real movement? I'm forever reading about the microbiome in things like Medical News today/BMJ etc. It's an exciting field to be investing in but are we at the very start? If so can we imagine there will be a few fund raises along the way before the business can really take off? What are other people' expectations?